74 results about "Alopecia areata" patented technology

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

The invention relates to the field of biological medicine, in particular to a hair follicle targeted delivery system and hair growth and hair loss prevention cosmetics, the hair follicle targeted delivery system comprises: a lipid nanoparticle core which is internally loaded with a bioactive component with hair growth and hair loss prevention effects; the hair follicle targeting molecule can specifically recognize and bind to a receptor on the surface of a hair follicle cell; a targeting anchoring conjugate composed of a linker covalently linked to the hair follicle targeting molecule and an anchoring lipid; wherein the targeting anchoring conjugate is embedded into the lipid bilayer of the lipid nanoparticle core through the anchoring lipid, so that the hair follicle targeting molecule is displayed on the surface of the lipid nanoparticle core. According to the application, through an innovative targeted anchoring conjugate structure, the targeting property and enrichment efficiency of hair growth and hair loss prevention active ingredients on hair follicle tissues can be remarkably improved, and the effect that a medicine accurately acts on a focus part is ensured, so that the number of hair follicles at an alopecia areata modeling part can be remarkably increased.

Disclosed is a method for preventing, treating, or ameliorating alopecia areata, comprising administering a therapeutically effective amount of a thyromimetic compound or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein said thyromimetic compound is a compound of Formula I, wherein R1,R2,R3,R4,R5,R6,R7,R8,R9,G,T,and X are defined as herein.

The invention belongs to the technical field of microorganisms, and particularly discloses lactobacillus paracasei and application thereof, the lactobacillus paracasei is named as lactobacillus paracasei Jlus66, the lactobacillus paracasei is preserved in China General Microbiological Culture Collection Center on March 31, 2021, the preservation address is No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No.22101. The lactobacillus paracasei is named as lactobacillus paracasei Jlus66. The lactobacillus paracasei Jlus66 has the obvious beneficial effects in the treatment of the alopecia areata, and the obvious beneficial effects comprise the immune regulation, the anti-oxidation and anti-inflammatory effects and the optimization of the intestinal tract-skin axis. In addition, the medicine is high in safety and small in side effect, so that the medicine becomes a promising adjuvant therapy means.

The invention discloses a small nucleic acid targeting androgen receptor AR, provides various modification methods, enhances sequence stability after modification, effectively knocks down AR mRNA, has a remarkable curative effect, and can be used together with various delivery prescriptions. The small nucleic acid provided by the invention can be efficiently delivered to a target spot through lipid nanoparticles, and also can be effectively delivered to cells without other delivery carriers by coupling an alkyl chain structure in a sequence. The small nucleic acid and the preparation method thereof provided by the invention can be used as a technical means for treating diseases caused by abnormal androgen expression or treating diseases related to androgen receptors, and the indications of the small nucleic acid include but are not limited to androgenetic alopecia, alopecia areata, neuropathic alopecia, scar alopecia, diffuse alopecia, acne and the like.

This invention relates to the field of biomedicine, and more particularly to a hair follicle-targeted delivery system and a hair growth and anti-hair loss cosmetic. The hair follicle-targeted delivery system comprises: a lipid nanoparticle core loaded with bioactive ingredients having hair growth and anti-hair loss effects; a hair follicle-targeting molecule capable of specifically recognizing and binding to receptors on the surface of hair follicle cells; and a targeting and anchoring conjugate consisting of a linker covalently linked to the hair follicle-targeting molecule and an anchoring lipid. The targeting and anchoring conjugate is embedded in the lipid bilayer of the lipid nanoparticle core via the anchoring lipid, thereby exposing the hair follicle-targeting molecule on the surface of the lipid nanoparticle core. This application, through its innovative targeting and anchoring conjugate structure, can significantly improve the targeting and enrichment efficiency of the hair growth and anti-hair loss active ingredients on hair follicle tissue, ensuring precise drug action on the lesion site, thereby significantly increasing the number of hair follicles in the alopecia areata modeling area.

The invention discloses a traditional Chinese medicine for treating alopecia areata. The traditional Chinese medicine is prepared from the following components in parts by weight: 0.15 part of menthol, 0.17 part of white vaseline, 0.3 part of glycerol, 0.8 part of liquid paraffin, 0.9 part of cortex dictamni, 0.1 part of radix sophorae flavescentis, 0.15 part of rheum officinale, 9-15 parts of poria cocos, 13-19 parts of herba lysimachiae, 13-19 parts of centipede, 5-11 parts of radix euphorbiae lantu, 15-21 parts of honeysuckle, 17-23 parts of horse oil, 11-17 parts of liquorice, 25-31 parts of aloe, 27-33 parts of radix arnebiae seu lithospermi, 0.5 part of borneol, 0.3 part of methyl salicylate and 0.9 part of zaocys dhumnade. The medicine has obvious effect on treating alopecia areata and small toxic and side effects.

The invention discloses a novel traditional Chinese medicine honeyed pill for treating alopecia, and relates to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: radix rehmanniae praeparata, angelica sinensis, raw radix paeoniae alba, semen cuscutae fried with wine, radix saposhnikoviae, gastrodia elata, ligusticum wallichii, radix ophiopogonis, asparagus cochinchinensis, radix bupleuri, radix puerariae, cassia twig, radix curcumae, caulis spatholobi and other traditional Chinese medicines which are subjected to superfine grinding and then are matched according to a specific proportion. The preparation process comprises the steps of crushing; refining honey; and mixing and waking up the medicine. The traditional Chinese medicine composition has the following effects: the composition takes effect at multiple targets: up-regulating hair follicle survival promoting factors and down-regulating inflammatory mediators; the process has the advantages that the stability of pills is improved by controlling the viscosity of refined honey; the clinical application has the advantages that the cure rate of severe alopecia totalis is improved compared with the traditional prescription The recurrence rate is low after the medicine is stopped for one year. The formula is mainly used for treating alopecia, alopecia areata, sticktight and alopecia totalis.

The invention provides a traditional Chinese medicine composition for treating alopecia areata and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition is prepared from the following components in parts by mass: 10 to 30 parts of radix rehmanniae recen, 10 to 30 parts of radix rehmanniae preparata, 10 to 30 parts of caulis spatholobi, 10 to 30 parts of caulis polygoni multiflori, 30 to 50 parts of radix astragali, 10 to 20 parts of rhizoma chuanxiong, 10 to 30 parts of radix paeoniae alba, 5 to 20 parts of rhizoma gastrodiae, 5 to 20 parts of cordyceps sinensis, 10 to 30 parts of herba ecliptae, 10 to 30 parts of mulberry and 5 to 20 parts of fructus chaenomelis. The effect is stronger, and no side effect exists. The tincture prepared by the invention is a pure external preparation without systemic toxicity, has no side effects such as hirsutism and skin atrophy after long-term use, and is especially suitable for sensitive scalp patients.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a tablet composition for treating alopecia areata and a preparation method thereof.The tablet composition is a composition comprising two main drugs including finasteride and baricitinib and is prepared by mixing and pressing finasteride particles and baricitinib particles which are prepared through specific auxiliary materials and a process, the finasteride granules and the baricitinib granules have good Karl index and Hausner ratio after being mixed, the pressed tablet composition has good performance in a plurality of test items such as acceleration for 6 months, long-term 6 months and high-humidity test, and the auxiliary material formula and the process can simultaneously meet the quality requirements of finasteride and baricitinib. Meanwhile, the degradation condition of the main medicine is relieved, the increase of related impurities of finasteride and baricitinib is reduced, the quality stability of the medicine under different storage conditions is improved, and the safety and effectiveness of the medicine within the period of validity and the integrity of the appearance of the tablet are ensured.

This invention belongs to the field of traditional Chinese medicine technology and discloses the application of *Saposhnikovia divaricata* in the preparation of drugs for treating alopecia areata. The preparation method of *Saposhnikovia divaricata* extract is as follows: *Saposhnikovia divaricata* is dried in the shade, pulverized, and then soaked in ethanol for at least 24 hours. The supernatant is then collected. This invention's *Saposhnikovia divaricata* extract can significantly shorten the time for skin to darken and the time for new hair to grow, enabling skin and hair to enter the growth phase more quickly. It can significantly increase the length and weight of newly grown hair and increase the number of primary hair follicles in the skin, thus promoting hair growth in alopecia areata and providing ideas and theoretical basis for the research and development of new drugs.

The present invention relates to a novel compound acting as a functional antagonist for S1PR1 and S1PR4, and a use thereof. The compound according to the present invention exhibits significantly excellent binding strength to S1PR1 and S1PR4 receptors, thus exhibiting an excellent effect in preventing or treating inflammatory bowel disease, alopecia areata (AA), or an autoimmune disease.

The application provides an application of a hair follicle immune homeostasis regulation strategy in treating alopecia diseases. A group of pathological LAMP3 + CCR7 + IL4I1 + DC3 dendritic cell subpopulation. A DC3 dendritic cell subpopulation marker gene Il4i1 Drive conditionally knockout one of the CGRP receptor complexes Calcrl The constructed spontaneous alopecia areata animal model can well simulate the progressive and active hair loss of alopecia areata patients, form stable hair loss patches, and combine with pathological changes such as hair follicle immune cell infiltration, which indicates that the dendritic cell CGRP signal loss is an important inducement for mediating systemic alopecia areata. The application also discloses a pharmaceutical composition or kit for preparing a drug for relieving / treating hair loss, improving hair follicle homeostasis, or enhancing hair growth / black coloration (reducing white hair), which comprises: (a) a JAK kinase inhibitor, and (b) a neuropeptide CGRP or a receptor agonist thereof.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

Provided herein are method of thyroid hormone receptor beta (THRβ) agonist and combinations comprising a glucagon-like peptide-1 receptor (GLP-1R) agonist and a thyroid hormone receptor beta (THRβ) agonist and methods comprising administering to a subject in need thereof such combinations.

The invention discloses a traditional Chinese medicine composition for caring scalp hair and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine preparations. The traditional Chinese medicine composition is blood-nourishing and hair-growing liquid and consists of traditional Chinese medicine powder and home-brewed white spirit, wherein the traditional Chinese medicine powder comprises radix polygoni multiflori preparata, fructus psoraleae, rhizoma drynariae, flos carthami, rhizoma chuanxiong, fructus cnidii, cortex dictamni, cacumen biotae and radix rehmanniae preparata, and the home-brewed white spirit is prepared by cooking, fermenting and distilling black glutinous rice, sorghum, black beans and triticale. The traditional Chinese medicine composition can be used for specifically solving the problems of hair follicle blockage, epifolliculitis, alopecia areata, alopecia, white hair and the like caused by large working pressure, staying up late, chemical washing and care residues and the like of modern people, is safe and mild, has no obvious adverse reaction, gives consideration to treatment and daily maintenance, and is wide in application range.

The invention belongs to the field of medicines, and discloses a finasteride-containing composition and application thereof. The composition comprises finasteride, graphene and more than one pharmaceutically acceptable auxiliary material. The composition can well prevent and / or treat alopecia, alopecia seborrhoeica, androgenetic alopecia and alopecia areata or promote hair growth, compared with finasteride tablets, the dosage of active ingredients of the composition is greatly reduced, related side effects of the active ingredients are relieved, and the composition is quick in effect taking, long in drug effect lasting time and good in curative effect.

To provide methods for the treatment and / or prevention of certain types of hair loss (also known as alopecia), including androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and senescent alopecia.SOLUTION: A method for treating a subject comprises providing a composition that includes or delivers a plasminogen activator inhibitor-1 (PAI-1) inhibitor, and administering the composition to a site of the subject such that the PAI-1 inhibitor is delivered to the subject, wherein the site comprises or has comprised a plurality of hair follicles each optionally containing a hair therein, and wherein the subject has one or more treatable conditions selected from the group consisting of androgenetic alopecia, alopecia areata, frontal fibrosing alopecia, and senescent alopecia.SELECTED DRAWING: None

The application discloses use of WEZ series compounds in preparation of products for preventing or / and treating alopecia. By establishing an animal model of alopecia, it is found that the compounds shown in formulas IV, V and VI have effects in treating alopecia and other similar hair loss diseases, including but not limited to androgen source alopecia (AGA) (also known as seborrheic alopecia) and alopecia areata.

The present disclosure relates to methods of treating alopecia areata (AA) using the selective JAK1 inhibitor upatinib.

The present invention provides compounds, compositions, and methods for treating alopecia areata (AA) in patients who require it.

The disclosure relates to a pharmaceutical composition comprising cyclosporine dissolved in a semifluorinated alkane and optionally a co-solvent, for use in the topical treatment of alopecia areata.

The invention discloses a traditional Chinese medicine external preparation for treating alopecia. The traditional Chinese medicine external preparation is prepared from polygonum multiflorum, cacumen biotae, salvia miltiorrhiza, angelica sinensis, ligusticum wallichii, eclipta, glossy privet fruit, garden balsam stem, ginger, borneol and liquorice according to a specific proportion. The preparation is designed on the basis of a kidney-tonifying, blood-activating and transdermal theory. Polygonum multiflorum-cacumen biotae serving as a monarch drug promotes hair follicle regeneration and inhibits androgen; the minister drug salvia miltiorrhiza-angelica sinensis-ligusticum wallichii is combined to improve microcirculation; and the adjuvant drugs of garden balsam stem, borneol and ginger construct a high-efficiency drug penetration system. The traditional Chinese medicine composition can be prepared into three dosage forms of tincture, gel and spray, wherein the tincture focuses on extraction of fat-soluble components; the gel prolongs the drug residence time; and non-contact administration of the spray is realized. The whole formula remarkably improves the hair density and diameter through a multi-target effect, and is especially suitable for seborrheic alopecia and alopecia areata. The curative effect of the traditional Chinese medicine composition is equivalent to that of chemical medicines, but the recurrence rate is lower after drug withdrawal, and no systematic side effect exists.

The invention relates to an indole derivative shown in general formula (I-1) and its use in preparing drugs for preventing and / or treating indications of S1P receptor related disorders. The indole derivative of the invention is replaced by R1, R2, R5, and R6 at different sites respectively, and the obtained modified indole derivative has excellent biological activity and is an ideal S1P receptor regulator with high efficiency. Compounds of general formula (I-1) can be used to treat and / or prevent Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, multiple sclerosis, atopic dermatitis, eosinophilic esophagitis, alopecia areata, primary cholangitis, pyoderma gangrenosum, graft-versus-host disease, amyotrophic lateral sclerosis, systemic lupus erythematosus, type I diabetes arteriosclerosis, atherosclerosis, scleroderma, autoimmune hepatitis, acne, microbial infection, viral infection, and other autoimmune and inflammatory diseases.

The present application relates to a pharmaceutical composition, comprising an active ingredient compound 1, a pharmaceutically acceptable polymer carrier, a surfactant and other pharmaceutically acceptable excipients, wherein the active ingredient, the polymer carrier and optionally at least a portion of the surfactant are present in the form of a solid dispersion. Disclosed in the present application is the pharmaceutical composition containing the compound 1 for the first time. The composition has stable product quality and good bioavailability. On the basis of the characteristic that the compound 1 is a JAK inhibitor, the composition has wide application prospects for alopecia areata, vitiligo, atopic dermatitis, psoriasis, membranous nephropathy, ankylosing spondylitis, peripheral T cell lymphoma, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, etc.

The invention relates to a compound preparation for treating alopecia areata, an active component A is a direct or indirect EPO receptor agonist, an active component B is tofacitinib or a pharmaceutically acceptable salt thereof, and the EPO receptor agonist is preferably rosaxostat. The compound preparation has the beneficial effects that the rosaxostat and the tofacitinib or the pharmaceutically acceptable salts thereof are limited when being independently used for treating the alopecia areata, but the rosaxostat and the tofacitinib or the pharmaceutically acceptable salts thereof just act on different targets in the alopecia areata pathogenesis respectively, so that the compound preparation is prepared, a key signal channel in the alopecia areata pathogenesis is inhibited through the rosaxostat, and the curative effect of the rosaxostat on the alopecia areata pathogenesis is improved. The defect that tofacitinib is insufficient in curative effect on moderate and severe patients is made up from the pathogenesis, meanwhile, the defect that tofacitinib is poor in hair repairing effect is improved from the symptom through the good hair growth promoting effect of the rosastat, the medicine effects of the tofacitinib and the rosastat are complementary, both symptoms and root causes are treated, and the tofacitinib and the rosastat can be combined according to the synergistic interaction. Appropriate reduction of the dosage of tofacitinib can reduce the risk of side effects.

Disclosed is a production method of a product that is developed for treatment of hair loss, alopecia areata (pelade or ringworm), androgenetic alopecia (AGA), hair follicle nourishment, scalp nourishment and scar, scar tissue, eczema, acne treatments, for neurodegenerative, inflammatory diseases and for immune modulation purposes (regulation of the immunological response against inflammation of human tissues and fluids, for regeneration purposes). In particular, the disclosed is a method for the production of a chemical-free product with amniotic fluid content, which has been standardized by pooling and then freeze-dried and gamma irradiated (pooled / cocktail and gamma irradiated amnion-OTIA 1.0), that has been developed to be used in the treatment of ailments such as hair loss, alopecia areata (pelade), androgenetic alopecia (AGA), hair follicle nutrition, scalp nourishment, scar, scar tissue, eczema and acne.

The present disclosure relates to a pharmaceutical composition comprising enavogliflozin as an active ingredient for preventing or treating alopecia areata. Enavogliflozin of the present disclosure increases β-hydroxybutyrate (BHB) to inhibit NLRP3 inflammasome and reduce IL-1β, and reduces the expression of inflammatory proteins such as NLRP3, Caspase-1, ASC, and IL-1β to alleviate inflammation associated with the onset of alopecia areata while decreasing the expression of NKG2D, which contributes to follicular destruction, thereby being able to be advantageously used to prevent or treat alopecia areata.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a preparation method and application of a compound traditional Chinese medicine tincture, and aims at solving the problems that an existing traditional Chinese medicine tincture is poor in stability, low in active ingredient utilization rate, low in transdermal efficiency and high in impurity content. Calcining the calcined native copper, ball-milling, and drying and crushing the composite medicinal material; 2, gradient targeted extraction: extracting fat-soluble components by ultrasonic-ultrahigh pressure pulse, and extracting water-soluble components by a functional extracting solution; 3, double-membrane purification; and 4, packaging: adding 0.1% phenoxyethanol, and carrying out nitrogen headspace filling in a brown bottle. According to the invention, the degradation rate of active ingredients is low, the yield is increased, the transdermal rate is high, the validity period is 12 months, the impurities are reduced, the traditional Chinese medicine composition can be used for preparing external medicines for treating alopecia areata and white hair and inhibiting alopecia, the single dose is 2-5mL, and the medication interval is 12 hours.

The invention relates to an application of a pyrrolopyrimidine compound and a composition of the pyrrolopyrimidine compound. The invention relates to application of a compound as shown in a formula I and pharmaceutically acceptable salt or pharmaceutical composition thereof in preparation of drugs for treating and / or preventing autoimmune skin diseases. The traditional Chinese medicine composition can effectively treat and / or prevent autoimmune skin diseases, especially atopic dermatitis, leucoderma and alopecia areata.